Accessibility Menu
Synlogic logo

Synlogic(OTC) SYBX

Current Price$0.71
Market Cap$8.25MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2017)-100%
5 Year-99%
1 Year-56%
1 Month-1%
Synlogic last closing stock price
MetricPriceDate
Last closeUSD 0.712026-07-22
Synlogic stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+1.4%USD 0.702026-07-15
1 month-1.24%USD 0.722026-06-22
3 month+13.34%USD 0.632026-04-23
Year to date-36.52%USD 1.122025-12-31
1 year-55.56%USD 1.602025-07-22
3 year-90.63%USD 7.592023-07-21
5 year-98.51%USD 47.702021-07-23
Since inception-99.61%USD 181.052017-08-28

Synlogic Financials at a Glance

Market Cap

$8.25MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$641.00K

EPS (TTM)

-$0.05

P/E Ratio

-15.36

Dividend

$0.00

Beta (Volatility)

0.91 (Low)

Price

$0.71

Volume

4,281

Open

$0.71

Previous Close

$0.71

Daily Range

$0.71 - $0.71

52-Week Range

$0.54 - $1.87

Estimated Earnings Date

May 6, 2026

SYBX News

493 gut microbiome

Will the Gut Microbiome Change Medicine? Wall Street Isn't Convinced.

Maxx ChatskoSep 17, 2019

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Synlogic

Synlogic develops oral medicines for rare metabolic and immune diseases. Its products aim to help people with inherited conditions process certain nutrients. These treatments are designed for patients who cannot break down specific substances in food.

Lab Bench to Lunchbox: Synlogic’s Main Offerings

  • Phenylketonuria (PKU) Candidates: SYNB1618 and SYNB1934, oral drugs for people with PKU, a rare disorder affecting protein breakdown. (0% of revenue; no product sales)
  • Homocystinuria (HCU) Candidate: SYNB1353, an oral treatment for HCU, a genetic disorder causing high homocysteine levels. (0% of revenue)
  • Enteric Hyperoxaluria Candidate: SYNB8802, an oral drug for patients with excess oxalate, which can cause kidney stones. (0% of revenue)
  • Cancer Therapy Candidate: SYNB1891, injected directly into tumors for certain cancers and lymphoma. (0% of revenue)
  • Preclinical Programs: Early research on treatments for gout, cystinuria, and inflammatory bowel disease. (0% of revenue)

Growth Spurts and Strategic Shifts

  • Discontinued Phase 3 trial for SYNB1934 in February 2024 after internal review.
  • Launched strategic review in early 2024, considering merger or sale options.
  • Restructured in 2024, reducing to one full-time employee and selling lab equipment.
  • Maintains collaborations with F. Hoffmann-La Roche Ltd and Ginkgo Bioworks.
  • Shifted focus to managing existing assets and strategic alternatives in 2025.

Why Synlogic’s Approach Stands Out

Synlogic uses engineered probiotic bacteria to deliver drugs directly to the gut, limiting side effects. Its platform allows for quick development of new treatments using a single bacterial strain. The company’s oral medicines are designed to be easily stopped and do not stay in the body long-term.

Five Things You Need to Know

  • Revenue was $0 in Q2 2025, down 100% from Q2 2023.
  • Net loss was $529,000 in Q2 2025, compared to $3.1 million net income in Q2 2024.
  • Cash and cash equivalents were $17.0 million as of June 30, 2025, down from $18.9 million at December 31, 2024.
  • Operating expenses were $777,000 in Q2 2025, compared to negative $16 million in Q2 2023.
  • Company has one full-time employee after 2024 restructuring.

Bottom Line

Synlogic has shifted from drug development to exploring strategic options after clinical setbacks. Its future depends on the outcome of ongoing reviews and available cash resources.

AI Generated • Apr 16, 2026

Industry

Biotechnology

Sector

Health Care

Employees

1

CEO

Mary Beth Dooley

Website

www.synlogictx.com

Headquarters

Winchester, MA 01890, US

SYBX Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-5.42%

Return on Capital

-33.79%

Return on Assets

-4.39%

Earnings Yield

-6.51%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$8.25MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

11.70M

Volume

4.28K

Avg. Volume

10.38K

Financials (TTM)

Gross Profit

$0.00

Operating Income

-$4.63M

EBITDA

-$3.57M

Operating Cash Flow

-$3.32M

Capital Expenditure

$0.00

Free Cash Flow

-$3.32M

Cash & ST Invst.

$14.11M

Total Debt

$0.00

Synlogic Performance Analysis

Synlogic annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 1,180,000-32.7%
20232023-12-31USD 3,371,000185.7%
20242024-12-31USD 8,000-99.8%
20252025-12-31USD 0N/A
Synlogic sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30N/A
Q32025-09-30N/A
Q42025-12-31N/A
Q12026-03-31N/A
Synlogic annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -13.83-15.7%
20232023-12-31USD -9.42-31.9%
20242024-12-31USD -1.92-79.7%
20252025-12-31USD -0.08-95.7%
Synlogic sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30-267.6%
Q32025-09-30-342.9%
Q42025-12-31168.4%
Q12026-03-31-61.5%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

$8.25MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$8.25M

N/A

Employees

1

N/A

Net Income

$681.00K

+114.8%

EBITDA

-$1.11M

-44.3%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$14.11M

-18.3%

Total Debt

$0.00

N/A

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$0.00

N/A

Return on Assets

-4.39%

N/A

Return on Invested Capital

-36.84%

N/A

Free Cash Flow

-$563.00K

+64.8%

Operating Cash Flow

-$563.00K

+64.8%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
CUPRCuprina Holdings (Cayman) Limited Class A Ordinary Shares
$3.30-13.84%
CRISCuris, Inc.
$4.94+4.00%
BCTXBriaCell Therapeutics Corp.
$3.60-4.00%
PCSAProcessa Pharmaceuticals, Inc.
$2.54+13.39%

Trending Stocks

Symbol / CompanyPricePrice Chg
TAT&T
$23.04+0.04%
ONDSOndas
$8.00+0.04%
SMCISuper Micro Computer
$30.56+0.20%
AALAmerican Airlines Group
$14.79-0.03%

Questions About SYBX

What is the current price of Synlogic?

Synlogic is trading at $0.71 per share.

What is the 52-week range for Synlogic?

Over the past 52 weeks, Synlogic has traded between $0.54 and $1.87.

How much debt does Synlogic have?

As of the most recent reporting period, Synlogic reported total debt of $0.00.

How much cash does Synlogic have on hand?

Synlogic reported $14.11M in cash and cash equivalents in its most recent financial results.

What is Synlogic’s dividend yield?

Synlogic does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services